Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX stock opened at $1.18 on Friday. The business has a fifty day simple moving average of $0.69 and a 200 day simple moving average of $1.96. Eagle Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $6.81.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC acquired a new stake in Eagle Pharmaceuticals in the second quarter valued at approximately $145,000. Creative Planning bought a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at $59,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at $453,000. RBF Capital LLC boosted its holdings in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 14,991 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Eagle Pharmaceuticals during the 3rd quarter worth $96,000. 85.36% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.